Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 2/2020

14.04.2020 | Research Article

A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation

verfasst von: Nijole Bernaitis, Michelle Bowden, Adam La Caze

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background Atrial fibrillation (AF) is a risk factor for stroke in older people. Oral anticoagulants can reduce stroke risk but they are commonly under prescribed in the elderly, often due to concerns regarding the risk of bleeding. Prescribing in aged care residents may also be further complicated by associated geriatric conditions such as dementia and risk of falls. Systematic assessment of stroke and bleed risk can help identify people with AF expected to benefit from anticoagulant therapy and optimise prescribing. Objective The aim of this study was to assess the prescribing of anticoagulants in elderly aged care residents in accordance with Australian guideline recommendations. Setting Nineteen aged care facilities across southeast Queensland. Method A clinical audit of anticoagulant therapy in aged care residents was conducted. Main outcome measure Information was collected from the records of residents with non-valvular AF to assess the risk of stroke and bleeding and compare this prescribing to current evidence-based guidelines for anticoagulation in AF. Results A total of 1754 residents were screened with 359 (20.4%) identified to have a diagnosis of non-valvular AF. There were 356 (99.2%) residents with non-valvular AF and a sufficiently high risk of stroke to warrant the use of an anticoagulant. Of these, 172 (48.3%) were prescribed an oral anticoagulant and 40 (11.2%) residents had a documented decision not to prescribe oral anticoagulants in their records. The majority of residents prescribed anticoagulation were receiving non-vitamin K antagonists (76.8%). The prescribed dose was consistent with recommendations for 44.8% of residents prescribed oral anticoagulant therapy. Conclusion Many residents with non-valvular AF and significant risk of stroke were not receiving oral anticoagulation despite a lack of documented reason for non-prescribing. Non-vitamin K antagonists were widely prescribed but dosing of these agents could still be improved. There remains a need to improve anticoagulant prescribing for aged care residents and optimise stroke prevention in this population.
Literatur
1.
Zurück zum Zitat Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest J. 2012;142(6):1489–98.CrossRef Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest J. 2012;142(6):1489–98.CrossRef
2.
Zurück zum Zitat Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167(6):2412–20.PubMedCrossRef Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167(6):2412–20.PubMedCrossRef
5.
Zurück zum Zitat Rozzini R, Sleiman I, Trabucchi M. Warfarin prescribing in nursing homes. J Am Geriatr Soc. 2011;59(1):183–4.PubMedCrossRef Rozzini R, Sleiman I, Trabucchi M. Warfarin prescribing in nursing homes. J Am Geriatr Soc. 2011;59(1):183–4.PubMedCrossRef
6.
Zurück zum Zitat Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot JM, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–6.PubMedCrossRef Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot JM, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–6.PubMedCrossRef
7.
Zurück zum Zitat Nishtala P, Castelino R, Peterson G, Hannan P, Salahudeen M. Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk. J Clin Pharm Ther. 2016;41(3):279–84.PubMedCrossRef Nishtala P, Castelino R, Peterson G, Hannan P, Salahudeen M. Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk. J Clin Pharm Ther. 2016;41(3):279–84.PubMedCrossRef
8.
Zurück zum Zitat Virdee MS, Stewart D. Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention. Int J Clin Pharm. 2017;39(1):173–80.PubMedCrossRef Virdee MS, Stewart D. Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention. Int J Clin Pharm. 2017;39(1):173–80.PubMedCrossRef
10.
Zurück zum Zitat Ziff OJ, Camm AJ. Individualized approaches to thromboprophylaxis in atrial fibrillation. Am Heart J. 2016;173:143–58.PubMedCrossRef Ziff OJ, Camm AJ. Individualized approaches to thromboprophylaxis in atrial fibrillation. Am Heart J. 2016;173:143–58.PubMedCrossRef
11.
Zurück zum Zitat Rossi S. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2018. Rossi S. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2018.
12.
Zurück zum Zitat Rosendaal F, Cannegieter S, Van der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.PubMedCrossRef Rosendaal F, Cannegieter S, Van der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.PubMedCrossRef
13.
Zurück zum Zitat Rojas-Fernandez CH, Goh J, Hartwick J, Auber R, Zarrin A, Warkentin M, et al. Assessment of oral anticoagulant use in residents of long-term care homes: evidence for contemporary suboptimal use. Ann Pharmacother. 2017;51(12):1053–62.PubMedCrossRef Rojas-Fernandez CH, Goh J, Hartwick J, Auber R, Zarrin A, Warkentin M, et al. Assessment of oral anticoagulant use in residents of long-term care homes: evidence for contemporary suboptimal use. Ann Pharmacother. 2017;51(12):1053–62.PubMedCrossRef
14.
15.
Zurück zum Zitat Wong CX, Brown A, Tse H-F, Albert CM, Kalman JM, Marwick TH, et al. Epidemiology of atrial fibrillation: the Australian and Asia-Pacific perspective. Heart Lung Circ. 2017;26(9):870–9.PubMedCrossRef Wong CX, Brown A, Tse H-F, Albert CM, Kalman JM, Marwick TH, et al. Epidemiology of atrial fibrillation: the Australian and Asia-Pacific perspective. Heart Lung Circ. 2017;26(9):870–9.PubMedCrossRef
16.
Zurück zum Zitat Lefebvre M-CD, St-Onge M, Glazer-Cavanagh M, Bell L, Nguyen JNK, Nguyen PV-Q, et al. The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can J Cardiol. 2016;32(2):169–76.PubMedCrossRef Lefebvre M-CD, St-Onge M, Glazer-Cavanagh M, Bell L, Nguyen JNK, Nguyen PV-Q, et al. The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can J Cardiol. 2016;32(2):169–76.PubMedCrossRef
17.
Zurück zum Zitat Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.PubMedCrossRef Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.PubMedCrossRef
18.
Zurück zum Zitat Katz DF, Maddox TM, Turakhia M, Gehi A, Obrien EC, Lubitz SA, et al. Contemporary trends in oral anticoagulant prescription in atrial fibrillation patients at low to moderate risk of stroke after guideline- recommended change in use of the CHADS2 to the CHA2DS2-VASc score for thromboembolic risk assessment: analysis from the National Cardiovascular Data Registry’s Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. Circulation. 2017;10(5):e003476.PubMed Katz DF, Maddox TM, Turakhia M, Gehi A, Obrien EC, Lubitz SA, et al. Contemporary trends in oral anticoagulant prescription in atrial fibrillation patients at low to moderate risk of stroke after guideline- recommended change in use of the CHADS2 to the CHA2DS2-VASc score for thromboembolic risk assessment: analysis from the National Cardiovascular Data Registry’s Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. Circulation. 2017;10(5):e003476.PubMed
19.
Zurück zum Zitat Patel AA, Nelson WW, Schein J. Impact of CHA2DS2VASc score on candidacy for anticoagulation in patients with atrial fibrillation: a multi-payer analysis. Clin Ther. 2016;38(10):2196–2203.e5.PubMedCrossRef Patel AA, Nelson WW, Schein J. Impact of CHA2DS2VASc score on candidacy for anticoagulation in patients with atrial fibrillation: a multi-payer analysis. Clin Ther. 2016;38(10):2196–2203.e5.PubMedCrossRef
20.
Zurück zum Zitat Lane DA, Lip GY. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–5.PubMedCrossRef Lane DA, Lip GY. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–5.PubMedCrossRef
21.
Zurück zum Zitat Obrien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167(4):601-9.e1. Obrien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167(4):601-9.e1.
22.
Zurück zum Zitat Bo M, Brunetti E. Oral anticoagulant therapy for older patients with atrial fibrillation. Geriatric Care. 2017;3(3):18–27.CrossRef Bo M, Brunetti E. Oral anticoagulant therapy for older patients with atrial fibrillation. Geriatric Care. 2017;3(3):18–27.CrossRef
23.
Zurück zum Zitat Orkaby AR, Ozonoff A, Reisman JI, Miller DR, Zhao S, Rose AJ. Continued use of warfarin in veterans with atrial fibrillation after dementia diagnosis. J Am Geriatr Soc. 2017;65(2):249–56.PubMedCrossRef Orkaby AR, Ozonoff A, Reisman JI, Miller DR, Zhao S, Rose AJ. Continued use of warfarin in veterans with atrial fibrillation after dementia diagnosis. J Am Geriatr Soc. 2017;65(2):249–56.PubMedCrossRef
24.
Zurück zum Zitat Moroney JT, Tseng CL, Paik MC, Mohr J, Desmond DW. Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. J Am Geriatr Soc. 1999;47(7):824–9.PubMedCrossRef Moroney JT, Tseng CL, Paik MC, Mohr J, Desmond DW. Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. J Am Geriatr Soc. 1999;47(7):824–9.PubMedCrossRef
25.
Zurück zum Zitat Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125(8):773–8.PubMedCrossRef Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125(8):773–8.PubMedCrossRef
26.
Zurück zum Zitat Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612–7.PubMedCrossRef Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612–7.PubMedCrossRef
27.
Zurück zum Zitat Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–85.PubMedCrossRef Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–85.PubMedCrossRef
28.
Zurück zum Zitat Culebras A, Messé SR, Chaturvedi S, Kase CS, Gronseth G. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(8):716–24.PubMedPubMedCentralCrossRef Culebras A, Messé SR, Chaturvedi S, Kase CS, Gronseth G. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(8):716–24.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.PubMedCrossRef Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.PubMedCrossRef
30.
Zurück zum Zitat Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–106.PubMedPubMedCentralCrossRef Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–106.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med. 2014;127(11):1075–82.PubMedCrossRef Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med. 2014;127(11):1075–82.PubMedCrossRef
32.
Zurück zum Zitat Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69(7):777–85.PubMedCrossRef Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69(7):777–85.PubMedCrossRef
33.
Zurück zum Zitat Schwill S, Krug K, Peters-Klimm F, van Lieshout J, Laux G, Szecsenyi J, et al. Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction. BMC Fam Pract. 2018;19(1):115.PubMedPubMedCentralCrossRef Schwill S, Krug K, Peters-Klimm F, van Lieshout J, Laux G, Szecsenyi J, et al. Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction. BMC Fam Pract. 2018;19(1):115.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Alamneh EA, Chalmers L, Bereznicki LR. The Tasmanian atrial fibrillation study: transition to direct oral anticoagulants 2011–2015. Cardiovasc Ther. 2017;35(3):e12254.CrossRef Alamneh EA, Chalmers L, Bereznicki LR. The Tasmanian atrial fibrillation study: transition to direct oral anticoagulants 2011–2015. Cardiovasc Ther. 2017;35(3):e12254.CrossRef
35.
Zurück zum Zitat Elewa H, El-Makaty H, Ali Z. Appropriateness of dabigatran and rivaroxaban prescribing in Qatar: a 5-year experience. J Cardiovasc Pharmacol Ther. 2018;23(2):155–61.PubMedCrossRef Elewa H, El-Makaty H, Ali Z. Appropriateness of dabigatran and rivaroxaban prescribing in Qatar: a 5-year experience. J Cardiovasc Pharmacol Ther. 2018;23(2):155–61.PubMedCrossRef
36.
Zurück zum Zitat Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gener Med. 2017;10:87.CrossRef Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gener Med. 2017;10:87.CrossRef
37.
Zurück zum Zitat Maffey M, Steel L, Gadowski T, Allard L, Tomlinson S. An audit of novel anticoagulant prescribing errors in non-valvular atrial fibrillation: an experience from a tertiary centre. Heart Lung Circ. 2018;27:S147.CrossRef Maffey M, Steel L, Gadowski T, Allard L, Tomlinson S. An audit of novel anticoagulant prescribing errors in non-valvular atrial fibrillation: an experience from a tertiary centre. Heart Lung Circ. 2018;27:S147.CrossRef
Metadaten
Titel
A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation
verfasst von
Nijole Bernaitis
Michelle Bowden
Adam La Caze
Publikationsdatum
14.04.2020
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 2/2020
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01025-0

Weitere Artikel der Ausgabe 2/2020

International Journal of Clinical Pharmacy 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.